Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta
Other Treatments Global Adoption
Outcomes in COVID-19 convalescent plasma studies
Home   
Share  
Tweet
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
All studies   Mortality   Ventilation   ICU   Hospitalization   Serious outcomes   Recovery   Viral clearance   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -10% 19 21,323 Improvement, Studies, Patients Relative Risk Mortality -10% 19 21,323 Ventilation -3% 7 1,188 ICU admission 49% 2 1,341 Hospitalization 23% 6 2,553 Progression 10% 7 1,724 Recovery -1% 4 12,436 Viral clearance 29% 4 796 RCTs 0% 18 17,357 RCT mortality 0% 18 17,357 Peer-reviewed 0% 16 17,294 Early -36% 5 1,508 Late -8% 14 19,815 Convalescent Plasma for COVID-19 c19early.org/cp Dec 2022 Favorsconv. plasma Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Alemany (DB RCT) 80% 0.20 [0.01-4.14] death 0/188 2/188 Gharbharan (DB RCT) -1% 1.01 [0.06-16.0] death 1/207 1/209 Tau​2​ = 0.49, I​2​ = 30.4%, p = 0.6 Early treatment -36% 1.36 [0.44-4.17] 13/753 10/755 -36% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Hsue (DB RCT) -212% 3.12 [0.14-71.7] death 1/16 0/18 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Ortigoza (DB RCT) 12% 0.88 [0.63-1.20] death 59/462 71/462 Sullivan (DB RCT) 86% 0.14 [0.01-2.75] death 0/592 3/589 Raad -240% 3.40 [2.29-5.02] death 284 (n) 3,682 (n) Tau​2​ = 0.11, I​2​ = 72.4%, p = 0.56 Late treatment -8% 1.08 [0.83-1.41] 1,702/8,443 1,638/11,372 -8% improvement All studies -10% 1.10 [0.86-1.42] 1,715/9,196 1,648/12,127 -10% improvement 19 convalescent plasma COVID-19 studies c19early.org/cp Dec 2022 Tau​2​ = 0.11, I​2​ = 66.2%, p = 0.46 Effect extraction pre-specified(most serious outcome) Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] 5/250 1/248 Alemany (DB RCT) 80% 0.20 [0.01-4.14] 0/188 2/188 Gharbharan (DB RCT) -1% 1.01 [0.06-16.0] 1/207 1/209 Tau​2​ = 0.49, I​2​ = 30.4%, p = 0.6 Early treatment -36% 1.36 [0.44-4.17] 13/753 10/755 -36% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] 1,399/5,795 1,408/5,763 Hsue (DB RCT) -212% 3.12 [0.14-71.7] 1/16 0/18 Bégin (RCT) -13% 1.13 [0.88-1.45] 156/625 69/313 Ortigoza (DB RCT) 12% 0.88 [0.63-1.20] 59/462 71/462 Sullivan (DB RCT) 86% 0.14 [0.01-2.75] 0/592 3/589 Raad -240% 3.40 [2.29-5.02] 284 (n) 3,682 (n) Tau​2​ = 0.11, I​2​ = 72.4%, p = 0.56 Late treatment -8% 1.08 [0.83-1.41] 1,702/8,443 1,638/11,372 -8% improvement All studies -10% 1.10 [0.86-1.42] 1,715/9,196 1,648/12,127 -10% improvement 19 convalescent plasma COVID-19 mortality results c19early.org/cp Dec 2022 Tau​2​ = 0.11, I​2​ = 66.2%, p = 0.46 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -163% 2.63 [0.43-9.10] 5/28 2/30 Gharbharan (DB RCT) 67% 0.33 [0.01-8.16] 0/207 1/209 Tau​2​ = 0.30, I​2​ = 22.8%, p = 1. Early treatment 0% 1.00 [0.28-3.54] 7/315 7/319 0% improvement Agarwal (RCT) 1% 0.99 [0.54-1.81] 19/227 19/224 Improvement, RR [CI] Treatment Control Bajpai (RCT) -221% 3.21 [0.38-27.4] 3/14 1/15 AlQahtani (RCT) 33% 0.67 [0.22-2.01] 4/20 6/20 Hsue (DB RCT) -425% 5.25 [0.27-102] 2/16 0/18 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.94 Late treatment -2% 1.02 [0.61-1.70] 28/277 26/277 -2% improvement All studies -3% 1.03 [0.65-1.63] 35/592 33/596 -3% improvement 7 convalescent plasma COVID-19 mechanical ventilation results c19early.org/cp Dec 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.92 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 67% 0.33 [0.07-1.60] 2/80 6/80 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.17 Early treatment 67% 0.33 [0.07-1.60] 2/80 6/80 67% improvement Sullivan (DB RCT) 25% 0.75 [0.17-3.32] 3/592 4/589 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.71 Late treatment 25% 0.75 [0.17-3.32] 3/592 4/589 25% improvement All studies 49% 0.51 [0.17-1.49] 5/672 10/669 49% improvement 2 convalescent plasma COVID-19 ICU results c19early.org/cp Dec 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Korley (RCT) 10% 0.90 [0.64-1.26] hosp. 51/257 56/254 Improvement, RR [CI] Treatment Control Alemany (DB RCT) -5% 1.05 [0.60-1.84] hosp. 22/188 21/188 Gharbharan (DB RCT) 39% 0.61 [0.28-1.34] hosp. 10/207 18/209 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.39 Early treatment 11% 0.89 [0.68-1.16] 83/652 95/651 11% improvement Bajpai (RCT) 25% 0.75 [0.55-1.04] hosp. time 14 (n) 15 (n) Improvement, RR [CI] Treatment Control AlQahtani (RCT) 22% 0.78 [0.57-1.07] hosp. time 20 (n) 20 (n) Sullivan (DB RCT) 54% 0.46 [0.26-0.80] hosp. 17/592 37/589 Tau​2​ = 0.02, I​2​ = 29.3%, p = 0.0064 Late treatment 30% 0.70 [0.54-0.90] 17/626 37/624 30% improvement All studies 23% 0.77 [0.64-0.92] 100/1,278 132/1,275 23% improvement 6 convalescent plasma COVID-19 hospitalization results c19early.org/cp Dec 2022 Tau​2​ = 0.01, I​2​ = 11.8%, p = 0.0045 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Alemany (DB RCT) 80% 0.20 [0.01-4.14] death 0/188 2/188 Gharbharan (DB RCT) -1% 1.01 [0.06-16.0] death 1/207 1/209 Tau​2​ = 0.49, I​2​ = 30.4%, p = 0.6 Early treatment -36% 1.36 [0.44-4.17] 13/753 10/755 -36% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Hsue (DB RCT) -212% 3.12 [0.14-71.7] death 1/16 0/18 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Ortigoza (DB RCT) 12% 0.88 [0.63-1.20] death 59/462 71/462 Sullivan (DB RCT) 86% 0.14 [0.01-2.75] death 0/592 3/589 Raad -240% 3.40 [2.29-5.02] death 284 (n) 3,682 (n) Tau​2​ = 0.11, I​2​ = 72.4%, p = 0.56 Late treatment -8% 1.08 [0.83-1.41] 1,702/8,443 1,638/11,372 -8% improvement All studies -10% 1.10 [0.86-1.42] 1,715/9,196 1,648/12,127 -10% improvement 19 convalescent plasma COVID-19 serious outcomes c19early.org/cp Dec 2022 Tau​2​ = 0.11, I​2​ = 66.2%, p = 0.46 Effect extraction pre-specified(most serious outcome) Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Alemany (DB RCT) -5% 1.05 [0.85-1.30] no recov. 188 (n) 188 (n) Improvement, RR [CI] Treatment Control Gharbharan (DB RCT) -1% 1.01 [0.88-1.16] no recov. 137/207 137/209 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.73 Early treatment -2% 1.02 [0.91-1.15] 137/395 137/397 -2% improvement Gharbharan (RCT) 12% 0.88 [0.49-1.60] no disch. 43 (n) 43 (n) Improvement, RR [CI] Treatment Control Recovery Co.. (RCT) -1% 1.01 [0.97-1.06] no disch. 1,963/5,795 1,941/5,763 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.74 Late treatment -1% 1.01 [0.96-1.06] 1,963/5,838 1,941/5,806 -1% improvement All studies -1% 1.01 [0.97-1.06] 2,100/6,233 2,078/6,203 -1% improvement 4 convalescent plasma COVID-19 recovery results c19early.org/cp Dec 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.66 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Alemany (DB RCT) -4% 1.04 [0.97-1.11] viral load 188 (n) 188 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.33 Early treatment -4% 1.04 [0.97-1.11] 0/188 0/188 -4% improvement Li (RCT) 76% 0.24 [0.07-0.64] viral+ 4/26 15/23 Improvement, RR [CI] Treatment Control Agarwal (RCT) 28% 0.72 [0.55-0.95] viral+ 56/173 76/169 Bajpai (RCT) 32% 0.68 [0.42-1.09] viral load 14 (n) 15 (n) Tau​2​ = 0.09, I​2​ = 59.2%, p = 0.021 Late treatment 41% 0.59 [0.37-0.92] 60/213 91/207 41% improvement All studies 29% 0.71 [0.48-1.05] 60/401 91/395 29% improvement 4 convalescent plasma COVID-19 viral clearance results c19early.org/cp Dec 2022 Tau​2​ = 0.11, I​2​ = 83.3%, p = 0.084 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Alemany (DB RCT) 80% 0.20 [0.01-4.14] death 0/188 2/188 Gharbharan (DB RCT) -1% 1.01 [0.06-16.0] death 1/207 1/209 Tau​2​ = 0.49, I​2​ = 30.4%, p = 0.6 Early treatment -36% 1.36 [0.44-4.17] 13/753 10/755 -36% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Hsue (DB RCT) -212% 3.12 [0.14-71.7] death 1/16 0/18 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Ortigoza (DB RCT) 12% 0.88 [0.63-1.20] death 59/462 71/462 Sullivan (DB RCT) 86% 0.14 [0.01-2.75] death 0/592 3/589 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.94 Late treatment 0% 1.00 [0.94-1.06] 1,702/8,159 1,638/7,690 0% improvement All studies 0% 1.00 [0.94-1.06] 1,715/8,912 1,648/8,445 0% improvement 18 convalescent plasma COVID-19 Randomized Controlled Trials c19early.org/cp Dec 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.97 Effect extraction pre-specified(most serious outcome) Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] 5/250 1/248 Alemany (DB RCT) 80% 0.20 [0.01-4.14] 0/188 2/188 Gharbharan (DB RCT) -1% 1.01 [0.06-16.0] 1/207 1/209 Tau​2​ = 0.49, I​2​ = 30.4%, p = 0.6 Early treatment -36% 1.36 [0.44-4.17] 13/753 10/755 -36% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] 1,399/5,795 1,408/5,763 Hsue (DB RCT) -212% 3.12 [0.14-71.7] 1/16 0/18 Bégin (RCT) -13% 1.13 [0.88-1.45] 156/625 69/313 Ortigoza (DB RCT) 12% 0.88 [0.63-1.20] 59/462 71/462 Sullivan (DB RCT) 86% 0.14 [0.01-2.75] 0/592 3/589 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.94 Late treatment 0% 1.00 [0.94-1.06] 1,702/8,159 1,638/7,690 0% improvement All studies 0% 1.00 [0.94-1.06] 1,715/8,912 1,648/8,445 0% improvement 18 convalescent plasma COVID-19 RCT mortality results c19early.org/cp Dec 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.97 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Alemany (DB RCT) 80% 0.20 [0.01-4.14] death 0/188 2/188 Gharbharan (DB RCT) -1% 1.01 [0.06-16.0] death 1/207 1/209 Tau​2​ = 0.49, I​2​ = 30.4%, p = 0.6 Early treatment -36% 1.36 [0.44-4.17] 13/753 10/755 -36% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Ortigoza (DB RCT) 12% 0.88 [0.63-1.20] death 59/462 71/462 Sullivan (DB RCT) 86% 0.14 [0.01-2.75] death 0/592 3/589 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.9 Late treatment 0% 1.00 [0.94-1.06] 1,698/8,129 1,637/7,657 0% improvement All studies 0% 1.00 [0.94-1.06] 1,711/8,882 1,647/8,412 0% improvement 16 convalescent plasma COVID-19 peer reviewed trials c19early.org/cp Dec 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.94 Effect extraction pre-specified(most serious outcome) Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Libster (DB RCT) 50% 0.50 [0.09-2.65] ventilation 2/80 4/80 Libster (DB RCT) 67% 0.33 [0.07-1.60] ICU 2/80 6/80 Libster (DB RCT) 48% 0.52 [0.29-0.94] progression 13/80 25/80 Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Balcells (RCT) -163% 2.63 [0.43-9.10] ventilation 5/28 2/30 Balcells (RCT) -23% 1.23 [0.56-1.89] progression 13/28 12/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Korley (RCT) 10% 0.90 [0.64-1.26] hosp. 51/257 56/254 Korley (RCT) 6% 0.94 [0.72-1.22] progression 77/257 81/254 Alemany (DB RCT) 80% 0.20 [0.01-4.14] death 0/188 2/188 Alemany (DB RCT) -5% 1.05 [0.60-1.84] hosp. 22/188 21/188 Alemany (DB RCT) -5% 1.05 [0.85-1.30] no recov. 188 (n) 188 (n) Alemany (DB RCT) -4% 1.04 [0.97-1.11] viral load 188 (n) 188 (n) Alemany (DB RCT) 4% 0.96 [0.88-1.05] viral load 188 (n) 188 (n) Gharbharan (DB RCT) -1% 1.01 [0.06-16.0] death 1/207 1/209 Gharbharan (DB RCT) 67% 0.33 [0.01-8.16] ventilation 0/207 1/209 Gharbharan (DB RCT) 14% 0.86 [0.59-1.22] progression 207 (n) 209 (n) Gharbharan (DB RCT) 42% 0.58 [0.33-1.02] progression 123 (n) 103 (n) Gharbharan (DB RCT) 39% 0.61 [0.28-1.34] hosp. 10/207 18/209 Gharbharan (DB RCT) -50% 1.50 [0.40-5.64] hosp. time 207 (n) 209 (n) Gharbharan (DB RCT) -1% 1.01 [0.88-1.16] no recov. 137/207 137/209 Gharbharan (DB RCT) -8% 1.1 [0.00-9e+04] recov. time 207 (n) 209 (n) Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Gharbharan (RCT) 12% 0.88 [0.49-1.60] no disch. 43 (n) 43 (n) Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Li (RCT) 15% 0.85 [0.53-1.18] no improv. 25/52 29/51 Li (RCT) 76% 0.24 [0.07-0.64] viral+ 4/26 15/23 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Avendaño-Solà (RCT) 93% 0.07 [0.00-1.19] progression 0/38 7/43 Avendaño-Solà (RCT) 92% 0.08 [0.00-1.40] progression 0/38 6/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Agarwal (RCT) -7% 1.07 [0.73-1.58] progression 44/235 41/229 Agarwal (RCT) 1% 0.99 [0.54-1.81] ventilation 19/227 19/224 Agarwal (RCT) 28% 0.72 [0.55-0.95] viral+ 56/173 76/169 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 Bajpai (RCT) -114% 2.14 [0.22-21.1] death 2/14 1/15 Bajpai (RCT) -221% 3.21 [0.38-27.4] ventilation 3/14 1/15 Bajpai (RCT) 25% 0.75 [0.55-1.04] hosp. time 14 (n) 15 (n) Bajpai (RCT) 32% 0.68 [0.42-1.09] viral load 14 (n) 15 (n) AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 AlQahtani (RCT) 33% 0.67 [0.22-2.01] ventilation 4/20 6/20 AlQahtani (RCT) 22% 0.78 [0.57-1.07] hosp. time 20 (n) 20 (n) Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Simonovich (RCT) 19% 0.81 [0.50-1.31] 7-point status 228 (n) 105 (n) Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Recovery Co.. (RCT) -1% 1.01 [0.97-1.06] no disch. 1,963/5,795 1,941/5,763 Hsue (DB RCT) -212% 3.12 [0.14-71.7] death 1/16 0/18 Hsue (DB RCT) -12% 1.12 [0.08-16.6] death 1/16 1/18 Hsue (DB RCT) -425% 5.25 [0.27-102] ventilation 2/16 0/18 Hsue (DB RCT) -425% 5.25 [0.27-102] progression 2/16 0/18 Hsue (DB RCT) -425% 5.25 [0.27-102] progression 2/16 0/18 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Bégin (RCT) -12% 1.12 [0.86-1.46] death 141/614 63/307 Bégin (RCT) -16% 1.16 [0.94-1.43] death/int. 199/614 86/307 Ortigoza (DB RCT) 12% 0.88 [0.63-1.20] death 59/462 71/462 Ortigoza (DB RCT) 1% 0.99 [0.66-1.47] death 35/463 39/463